Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.47 |
| ▸ | FABP6 | P51161 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | MASP2 | O00187 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5681325 | 0.93 | HTR3E (0.49) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL5682259 | 0.86 | CACNA1H (0.62) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL2418522 | 0.83 | EGLN1 (0.49) | CACNA1HEGLN1NPY5RARCACNA1G | |
| SCHEMBL14531739 | 0.80 | EGLN1 (0.47) | CACNA1HEGLN1NPY5RARCACNA1G | |
| SCHEMBL13408169 | 0.80 | MAPT (0.57) | CACNA1HEGLN1NPY5RARCACNA1G | |
| SCHEMBL7795887 | 0.80 | EGLN1 (0.47) | CACNA1HEGLN1NPY5RARCACNA1G | |
| SCHEMBL216056 | 0.80 | HTR3E (0.60) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL14655355 | 0.79 | HTR3E (0.42) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| SCHEMBL11363828 | 0.79 | CACNA1H (0.46) | HTR3EHTR3BHTR3ABACE1HTR3D | |
| Hydrochloric Acid SCHEMBL30633447 | 0.78 | HTR3E (0.58) | HTR3EHTR3BHTR3ABACE1HTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653951-B1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| US-7691886-B2 | Benzimidazole derivatives as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| EP-1653951-A1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| EP-1620413-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005004864-A1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004098494-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010560-A1 | angiogenesis, in particular in tumors, restenoses, diabetic retinopathy, macular degenerative disease or rheumatoid arthritis | BRAF, RAF1, VEGFA | HTR3E 3678/4885HTR3B 3438/4885HTR3A 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.